AOD-9604: The Anti-Obesity Peptide Research

AOD-9604: A Modified Growth Hormone Fragment

AOD-9604 (Advanced Obesity Drug-9604) is a synthetic peptide consisting of amino acids 177-191 of human growth hormone, with an added tyrosine residue at the N-terminus. It was developed by Metabolic Pharmaceuticals in Australia with the goal of isolating the fat-reducing properties of growth hormone while eliminating its growth-promoting and diabetogenic effects.

The concept behind AOD-9604 is elegant: growth hormone has multiple biological activities, and by using only the fragment responsible for fat metabolism, researchers aimed to create a safer, more targeted anti-obesity agent.

Mechanism of Action

AOD-9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) through mechanisms similar to the lipolytic domain of natural growth hormone but without binding to the growth hormone receptor. Key aspects of its mechanism include:

• Stimulation of beta-3 adrenergic receptors involved in fat metabolism
• Enhancement of fat oxidation in adipose tissue
• Inhibition of new fat cell formation
• No effect on IGF-1 levels, distinguishing it from full-length GH
• No impact on blood glucose or insulin sensitivity at studied doses

Clinical Trial History

Phase I Trials

Initial Phase I safety studies demonstrated that AOD-9604 was well-tolerated in healthy volunteers with no significant adverse effects. Both oral and injectable formulations were tested.

Phase IIa Trial

A Phase IIa clinical trial in obese subjects showed encouraging results. An oral formulation of AOD-9604, administered at 1 mg daily for 12 weeks, produced statistically significant weight loss compared to placebo. The highest-dose group lost an average of 2.6 kg more than placebo.

Phase IIb Trial

However, the subsequent Phase IIb trial was less successful. At doses of 1 mg, 5 mg, and 10 mg oral AOD-9604 over 24 weeks, no statistically significant difference in weight loss was observed between AOD-9604 and placebo groups. This disappointing result effectively ended the development of AOD-9604 as a standalone oral obesity treatment by Metabolic Pharmaceuticals.

The Pivot to Joint Health

Despite its failure as an oral weight loss agent, AOD-9604 found new life in joint health research. Calzada Ltd., the successor to Metabolic Pharmaceuticals, pursued intra-articular (joint injection) applications for osteoarthritis.

Preclinical studies suggested that AOD-9604 could promote cartilage repair and proteoglycan synthesis when delivered directly to joint tissues. The peptide received GRAS (Generally Recognized As Safe) status from Australia's Therapeutic Goods Administration, supporting its favorable safety profile.

Clinical trials for the joint health application are ongoing, with preliminary results suggesting potential benefits for knee osteoarthritis when administered via intra-articular injection.

AOD-9604 in Current Practice

Despite its mixed clinical trial history, AOD-9604 remains popular in certain peptide therapy clinics. It is typically used as part of broader protocols rather than as a standalone treatment, often combined with other fat loss strategies or GH secretagogues.

Common Clinical Uses

• Adjunctive fat loss support alongside diet and exercise programs
• Intra-articular injection for joint pain and osteoarthritis
• Combination protocols with GH secretagogues or GLP-1 agonists

Safety Profile

AOD-9604 has a well-established safety profile from its clinical trial program:

• No significant effect on blood glucose or insulin levels
• No impact on IGF-1 or growth hormone levels
• GRAS status from the Australian TGA
• Well-tolerated across all clinical trial doses
• No evidence of antibody formation against AOD-9604

This favorable safety profile is one of AOD-9604's strongest assets, even if its efficacy for weight loss fell short of expectations.

AOD-9604 vs. Other Fat Loss Peptides

Compared to GLP-1 agonists like semaglutide, AOD-9604's weight loss effects are modest. The GLP-1 agonists work through powerful appetite suppression mechanisms that AOD-9604 lacks. Compared to GH secretagogues, AOD-9604 offers the theoretical advantage of targeting fat metabolism without broader GH effects, but the clinical evidence for meaningful fat loss is weaker.

Conclusion

AOD-9604 represents an instructive case study in peptide development. Its elegant concept of isolating growth hormone's fat-reducing activity was sound, but the clinical results did not match the preclinical promise for oral obesity treatment. The pivot to joint health applications may yet validate the peptide's therapeutic potential. For fat loss specifically, the evidence supports GLP-1 agonists far more strongly than AOD-9604. However, its excellent safety profile and potential joint health benefits keep it relevant in peptide research and clinical practice.